Pro-inflammatory IL-1 and IL-6 was identified as the key mediators of CRS in CAR-T therapies; therefore, IL-6/IL-6R blockade has been suggested as potential approaches to eliminate CRS. The gene discussed is IL6; the disease is congenital rubella syndrome.